Carbohydrate (i.e., Saccharide Radical Containing) Doai Patents (Class 514/23)
  • Patent number: 10226439
    Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 12, 2019
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
  • Patent number: 10213452
    Abstract: The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: February 26, 2019
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Abelardo Isaac Aguilera Peralta, Manuel Lopez-Cabrera, Rafael Selgas Gutierrez, Sonja Steppan, Jutta Passlick-Deetjen
  • Patent number: 10201179
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 12, 2019
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 10202623
    Abstract: An object of the present invention is to provide a series of techniques for producing 1,4-butanediol from methanol or the like. Provided is a recombinant cell prepared by introducing a gene encoding at least one enzyme selected from the group consisting of succinate semialdehyde dehydrogenase, succinyl-CoA synthase, CoA-dependent succinate semialdehyde dehydrogenase, 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyryl-CoA transferase, 4-hydroxybutyryl-CoA reductase, 4-hydroxybutyraldehyde dehydrogenase, and alcohol dehydrogenase, into a host cell which is a methylotroph, wherein the gene is expressed in the host cell, and the recombinant cell is capable of producing 1,4-butanediol from at least one C1 compound selected from the group consisting of methane, methanol, methylamine, formic acid, formaldehyde, and formamide.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: February 12, 2019
    Assignee: SEKISUI CHEMICAL CO., LTD.
    Inventors: Masahiro Furutani, Akihiro Uenishi, Koichiro Iwasa
  • Patent number: 10195227
    Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 5, 2019
    Assignee: L&F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10183038
    Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 22, 2019
    Assignee: L&F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10182998
    Abstract: The present disclosure provides a novel pharmaceutical composition for treating a malignant pleural effusion (MPE), including a benzenesulfonamide derivative and a pharmaceutically acceptable excipient. The present disclosure further provides a method for treating MPE by using the pharmaceutical composition.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: January 22, 2019
    Assignee: Gongwin Biopharm Holdings Co., Ltd.
    Inventors: Chuan-Ching Yang, Mao-Yuan Lin
  • Patent number: 10183053
    Abstract: Multi-component formulations comprise methylsulfonylmethane, fructose 1,6-diphosphate, and just one of trehalose, green tea extract, ashwagandha, and rutin, or a combination thereof. Multi-component formulations can prevent, delay, or treat cognitive decline, Alzheimer's disease, and other dementias.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 22, 2019
    Inventor: Gene S. Rosen
  • Patent number: 10174010
    Abstract: The present invention relates to canagliflozin Monohydrate and its crystalline forms, which as compared to the prior art, have higher stability in water or aqueous system, are more suitable for wet granulation processes or suspension preparations and have good storage stability; the present invention also relates to preparation methods of canagliflozin Monohydrate and its crystalline forms, pharmaceutical compositions thereof and uses thereof in preparation of drugs for treating diseases such as diabetes, diabetes complications, obesity and so on.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: January 8, 2019
    Assignee: HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Xiaoxia Sheng, Xiaohong Sheng, Kun Zhao, Xiaoye Song
  • Patent number: 10165792
    Abstract: The hunger minimized fasting system relies on providing a blood glucose level at all times in the range of 5 to 10 mM, satisfying glucose needs of the brain and metabolizing blood glucose through anaerobic glycolysis to release ATP at the extramitocontrial portion of the cell. Consuming only solid free nutrient liquids eliminates brain hunger response. Liquids consumed during fasting include solid filtered vegetable soup and clear fruit juices of 8 to 12 ounces taken every 2 to 4 hours having calorie deficiency of 600 to 1400 as compared to minimal daily calorie requirements for an adult. Fat released from storage is metabolized by ATP produced by glycolysis at the extramitocontrial location and enters the interior of the mitochondria, enabling the TCA cycle. Weight loss observed during fasting is about one half to one pound per day.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: January 1, 2019
    Inventors: Sudarshan Narasimhan, Dave Narasimhan
  • Patent number: 10117834
    Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 6, 2018
    Assignee: BIOGEN CHESAPEAKE LLC
    Inventor: Sven Jacobson
  • Patent number: 10093616
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: October 9, 2018
    Assignee: THERACOS SUB, LLC
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • Patent number: 10092495
    Abstract: The invention concerns a use of C7 sugars and derivatives of formula (I), called avocado perseose, which have, inter alia, a protective activity to epidermal skin cells. These C7 sugars and derivatives are capable of maintaining the expression of markers of adult stem cells, in particular basal stem cells. Avocado perseose can also be used for preventing the deleterious effects of environmental damage. Avocado perseose has a beneficial effect on the conservation of the potential of epidermal stem cells and thus helps maintain skin homeostasis.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: October 9, 2018
    Assignee: LABORATOIRE EXPANSCIENCE
    Inventors: Philippe Msika, Caroline Baudouin
  • Patent number: 10076131
    Abstract: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: September 18, 2018
    Assignee: Nestec S.A.
    Inventors: Yasaman Shahkhalili, Kevin Acheson, Katherine Mace, Julie Moulin, Irene Zbinden, Olivier Aprikian, Theresa Voss
  • Patent number: 10071057
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: September 11, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10071032
    Abstract: Compositions and methods of treating and/or preventing conditions of the oral cavity, e.g. gingivitis, comprise applying a toothpaste composition comprising at least 5% sodium chloride in a toothpaste base comprising a zinc salt, non-silica calcium carbonate abrasive and humectant, to the oral surfaces, e.g., the teeth and gums, of a patient in need thereof.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: September 11, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Yun Xu, Dorathy Zeng, Kahn Tan, Pingdong Li
  • Patent number: 10039709
    Abstract: Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: August 7, 2018
    Assignee: TRILOGIC PHARMA LLC
    Inventors: Hemant H. Alur, James A. H. Harwick, Mondal Pravakar, Thomas P. Johnston
  • Patent number: 10022389
    Abstract: New drugs useful in the prevention or treatment of constipation are provided, in which SGLT1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (I), or pharmaceutically acceptable salts thereof are contained as an active ingredient:
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 17, 2018
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Daisuke Yamamoto, Fusayo Io, Koji Yamamoto
  • Patent number: 10023600
    Abstract: Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: July 17, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Thomas Butler, Aesop Cho, Benjamin R. Graetz, Choung U. Kim, Samuel E. Metobo, Oliver L. Saunders, Andrew W. Waltman, Jie Xu, Lijun Zhang
  • Patent number: 9987222
    Abstract: The present invention relates to a method for the administration of a probiotic composition to a vaginal cavity and to compositions, devices and kits for use in this method.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: June 5, 2018
    Assignee: BIOSOMA B.V.
    Inventor: Floris Koumans
  • Patent number: 9969788
    Abstract: The present invention is directed to proteins in which a heparin binding peptide is fused to a growth factor that promotes cell growth and survival. The compound thus formed is bound to the surface of cells which are then administered to damaged tissue. The growth factor is thereby maintained at the site of administration where it promotes repair.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: May 15, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Richard Lee
  • Patent number: 9949997
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 24, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • Patent number: 9949998
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 24, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • Patent number: 9949996
    Abstract: The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 24, 2018
    Assignee: GRI BIO, INC.
    Inventor: Vipin Kumar Chaturvedi
  • Patent number: 9943098
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
    Type: Grant
    Filed: December 26, 2016
    Date of Patent: April 17, 2018
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 9937125
    Abstract: The invention provides intradialytic parenteral nutrition (IDPN) solutions with low carbohydrate for the treatment of malnutrition in dialysis patients. The IDPN solutions of the invention are particularly advantageous for the treatment of malnutrition in patients who are diabetic or suffer from other glucose management related pathologies or patients who require strict fluid management.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: April 10, 2018
    Assignee: Pentec Health, Inc.
    Inventor: Eileen Moore
  • Patent number: 9918870
    Abstract: A method of treating snoring and/or OSA in a subject in need of such treatment. The method includes crosslinking proteins of the subject's soft palate tissue or pharynx tissue. The crosslinking can occur by contacting the soft palate or pharynx tissue with a crosslinking reagent. In addition, the crosslinking can occur without heating, contracting or denaturing of the tissue, or any combination thereof.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: March 20, 2018
    Assignee: Orthopeutics, L.P.
    Inventors: Thomas P. Hedman, Pawel Slusarewicz
  • Patent number: 9907848
    Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: March 6, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Mark A. Exley, Lydia Lynch, Donal O'Shea, Cliona O'Farrelly, Steven P. Balk
  • Patent number: 9895389
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 20, 2018
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang
  • Patent number: 9884853
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: February 6, 2018
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Mitchell, Naomi Went
  • Patent number: 9873714
    Abstract: The present invention relates to processes for preparing a glucopyranosyl-substituted benzyl-benzene derivative of general formula III, wherein R1 is defined according to claim 1.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: January 23, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Weber, Tobias Fiedler, Christian Filser, Rainer Hamm, Simone Orlich, Matthias Post, Svenja Renner, Xiao-Jun Wang, Thomas Wirth
  • Patent number: 9861646
    Abstract: A dental composition comprising a therapeutically effective amount of doxycycline hyclate and a therapeutically effective amount of triamcinolone acetonide and use in dental treatment.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: January 9, 2018
    Assignee: OZDENT PTY LTD
    Inventor: Joshua George Tadros
  • Patent number: 9861575
    Abstract: A nutrition infusion is provided for administration through a peripheral vein that contains a vitamin B group and vitamin C stably and includes two solutions of a sugar solution and an amino acid solution. In the nutrition infusion for administration through a peripheral vein, the sugar solution contains vitamin B1, vitamin B12, and pantothenic acid and has a pH of 4.7 to 5.5, and the amino acid solution contains vitamin B2, folic acid, vitamin C, and biotin and has a pH of 7.0 to 7.5.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: January 9, 2018
    Assignee: EA Pharma Co., Ltd.
    Inventors: Kazuhiro Abiko, Toshiyuki Katsura
  • Patent number: 9854811
    Abstract: The present invention includes compositions and methods for the treatment of plants against pathogens, elimination of insects and to increase the shelf-life of fruits and vegetables that includes coating the plant with undiluted aloe vera gel.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: January 2, 2018
    Assignee: Coats Agri Aloe, LLC
    Inventor: Billy C. Coats
  • Patent number: 9849103
    Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: December 26, 2017
    Inventor: Young Hee Ko
  • Patent number: 9834573
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: December 5, 2017
    Assignee: Theracos Sub, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Patent number: 9828366
    Abstract: The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 28, 2017
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Ji Sook Kim, Won Jeoung Kim, Wook Jang, Ji Young Song, Moon Sub Lee, Nam Du Kim, Kwee Hyun Suh
  • Patent number: 9827267
    Abstract: The use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome or colpoxerosis disease in a mammal. Various tests, vaginal smooth muscle contractility test using New Zealand White Rabbit; (Experimental example 1); the effect on the vagina contractility in volunteers by using perinometer (Experimental example 2); and the effect on the colpoxerosis disease in volunteers (Experimental example 3), showed improving effect on the contractility of vagina tissue and colpoxerosis disease. Accordingly, the combination can be useful in treating or preventing lax vagina syndrome or colpoxerosis disease.
    Type: Grant
    Filed: September 11, 2016
    Date of Patent: November 28, 2017
    Inventor: Won Seog Choi
  • Patent number: 9815810
    Abstract: A method of cannabinoid preservation includes separating a cannabinoid ethanol (EtOH) mixture from a cannabis extract through a filtration process; forming a slurry by combining a crystalline compound with the cannabinoid EtOH mixture; heating and agitating the slurry in a pressurized chamber to form a colloidal cannabinoid EtOH mixture; distributing the colloidal cannabinoid EtOH mixture into a tray to form an evenly distributed mixture layer; forming an evaporation vessel for the evenly distributed mixture layer through the attachment of a detachable cover to the tray; positioning and heating the evaporation vessel within a heating chamber; performing a rapid cools process as the evenly distributed mixture layer approaches approaches saturation temperature; repeating the rapid cooling process until crystal formation is detected within the evenly distributed mixture layer; and/or removing the evaporation vessel from the heating chamber upon detection of crystal formation.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: November 14, 2017
    Assignee: DEEP CELL INDUSTRIES INC.
    Inventors: Kelly Ogilvie, Gary Bonilla
  • Patent number: 9795589
    Abstract: The present invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin A and the methods to synthesize such diterpenoid derivatives. In particular, the chemical entities of such synthetic diterpene compounds in the manufacture of a medicament is for the treatment of tumors or cancers.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: October 24, 2017
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Hongjie Zhang, Man Shing Ricky Wong, Lei Guo, Siu Wai Tsang, Kanglun Liu, Tongxin Zhang
  • Patent number: 9782330
    Abstract: Described herein are systems for removing selected components, e.g., stabilizing agents or preservatives, from a liquid composition just prior to use, using activated charcoal or an affinity matrix filter, together with variant and alternative designs, methods of making and using the product, and components thereof.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: October 10, 2017
    Assignee: Colgate-Palmolive Company
    Inventors: Guofeng Xu, Steven Miller, Jennifer Gronlund
  • Patent number: 9775854
    Abstract: Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: October 3, 2017
    Assignees: Indiana University Research and Technology Corporation, UAB Research Foundation
    Inventors: Bruce A. Molitoris, David M. Bedwell, Ruben M. Sandoval
  • Patent number: 9750245
    Abstract: The present document describes a method of reducing a microbial presence on at least one part of a subject by topically contacting the subject's part with an antimicrobial formulation comprising: a) at least one antimicrobial isolated or synthetic phenolic compound of natural origin; b) at least one surfactant sufficient to form a solution or dispersion of said phenolic compound in an aqueous carrier; c) a solvent for dissolving said phenolic compound; and d) a sufficient aqueous carrier quantity to make 100% (w/w).
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: September 5, 2017
    Assignee: LABORATOIRE M2
    Inventors: Gaetan Lemire, Ulysse Desranleau Dandurand, Sylvain Quessy, Ann Letellier
  • Patent number: 9730951
    Abstract: The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: August 15, 2017
    Assignee: VOLANT HOLDINGS GMBH
    Inventors: Joseph M. Fayad, Jerome Schentag
  • Patent number: 9717790
    Abstract: The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: August 1, 2017
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, David Samuel Larsen, Gavin Frank Painter
  • Patent number: 9707263
    Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: July 18, 2017
    Assignee: WORLD FORCE TECHNOLOGIES, LLC
    Inventors: Thomas W. Konowalchuk, Jack Konowalchuk
  • Patent number: 9695209
    Abstract: Amphiphilic calixarene glycoside compounds, the preparation of such compounds, and the use of such compounds for selectively extracting, solubilizing and stabilizing membrane proteins.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 4, 2017
    Assignee: CALIXAR
    Inventor: Julien Dauvergne
  • Patent number: 9693942
    Abstract: The present invention relates generally to the field of enhancing skin appearance. One aspect of the invention aims to provide a composition comprising 4-oxo-2-pentenoic acid for use in the reduction or prevention of regions of the skin with darker pigmentation. The present invention also relates to cosmetic use of a composition comprising 4-oxo-2-pentenoic acid for the reduction or prevention of regions of the skin with darker pigmentation.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: July 4, 2017
    Assignee: Nestec S.A.
    Inventors: Francia Jacqueline Arce Vera, Bertrand Bourqui, Timo Buetler, Stephane Duboux, Francis Foata, Marjorie Guitard, Philippe Alexandre Guy, Nicolas Page, Serge Andre Dominique Rezzi
  • Patent number: 9682099
    Abstract: Compositions and methods are disclosed for the treatment of osteoarthritis. The compositions comprising combinations of hyaluronic acid, glucosamine, and chondroitin sulfate, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: June 20, 2017
    Assignee: DEPUY SYNTHES PRODUCTS, INC.
    Inventors: Brooks J. Story, Scott A. Wadsworth, William R. Parrish, Uri Herzberg, Donna Torres, Benjamin A. Byers, Julia Hwang, Dongling Su
  • Patent number: RE46762
    Abstract: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 27, 2018
    Assignee: GILEAD SCIENCES, INC
    Inventors: Thomas Butler, Aesop Cho, Choung U. Kim, Jay P. Parrish, Oliver L. Saunders, Lijun Zhang